| scholarly article | Q13442814 |
| P356 | DOI | 10.1172/JCI115619 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC442886 |
| https://europepmc.org/articles/PMC442886?pdf=render | ||
| P932 | PMC publication ID | 442886 |
| P698 | PubMed publication ID | 1737845 |
| P50 | author | Jürg H Beer | Q52730900 |
| P2093 | author name string | N. Mohandas | |
| B. S. Coller | |||
| L. E. Scudder | |||
| K. T. Springer | |||
| K. J. Norton | |||
| S. M. West | |||
| P2860 | cites work | Amino-acid sequence and oligosaccharide attachment sites of human erythrocyte glycophorin | Q24564450 |
| Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 | ||
| Tissue sulfhydryl groups | Q26778486 | ||
| Fresh, Disintegrated Platelets in Radiation Thrombocytopenia: Correction of Prothrombin Consumption without Correction of Bleeding | Q33356441 | ||
| Effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia | Q33356457 | ||
| The Bra/Brb alloantigen system on human platelets | Q33414520 | ||
| Frozen autologous platelet transfusion for patients with leukemia | Q33479975 | ||
| A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa | Q33821916 | ||
| Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment | Q34237060 | ||
| A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex | Q34541247 | ||
| Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel | Q34571418 | ||
| Analysis of factors regulating erythrocyte deformability | Q36589191 | ||
| Osmotic gradient ektacytometry: comprehensive characterization of red cell volume and surface maintenance | Q36632392 | ||
| Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment | Q37695768 | ||
| Blood group-active surface molecules of the human red blood cell | Q37908396 | ||
| Binding specificities of eight monoclonal antibodies to human glycophorin A--studies with McM, and MkEn(UK) variant human erythrocytes and M- and MNV-type chimpanzee erythrocytes. | Q38353208 | ||
| Loss of membrane phospholipid asymmetry during activation of blood platelets and sickled red cells; mechanisms and physiological significance | Q38766526 | ||
| Alternate sources and substitutes for therapeutic blood components | Q39369676 | ||
| Reconstruction of platelet proteins into phospholipid vesicles. Functional proteoliposomes | Q40917716 | ||
| Assembly and secretion of recombinant human fibrinogen | Q41691022 | ||
| A water-soluble, monitorable peptide and protein crosslinking agent | Q42220034 | ||
| Collection and transfusion of blood in the United States, 1982-1988. | Q43451949 | ||
| Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. | Q44355152 | ||
| Inhibition of malarial parasite invasion by monoclonal antibodies against glycophorin A correlates with reduction in red cell membrane deformability | Q56380169 | ||
| Platelet membrane glycoprotein IIb-IIIa complex incorporated into phospholipid vesicles. Preparation and morphology | Q67275230 | ||
| Resolution and reconstitution of interplatelet recognition during aggregation | Q67963621 | ||
| Platelet GPIIb-IIIa: molecular variations and alloantigens | Q68022171 | ||
| Biotinylated erythrocytes: in vivo survival and in vitro recovery | Q68180023 | ||
| Inhibition of intravascular platelet aggregation by endothelium-derived relaxing factor: reversal by red blood cells | Q68902388 | ||
| Glycoproteins IIb and IIIa and platelet thrombospondin in a liposome model of platelet aggregation | Q69995638 | ||
| Platelet-platelet recognition during aggregation: distinct mechanisms determined by the release reaction | Q71409219 | ||
| Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia | Q71493148 | ||
| Passive participation of fixed platelets in aggregation facilitated by covalently bound fibrinogen | Q71727057 | ||
| Phosphatides as platelet substitutes in blood coagulation | Q78544718 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 546-555 | |
| P577 | publication date | 1992-02-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions | |
| P478 | volume | 89 |
| Q33435484 | Alternatives to allogeneic platelet transfusion. |
| Q39179984 | Bio-inspired nanomedicine strategies for artificial blood components |
| Q47324534 | Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding. |
| Q40657043 | Cellular adhesion molecules. |
| Q33560053 | Current concepts in platelet transfusion |
| Q26801300 | Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier |
| Q37700751 | Drug delivery by red blood cells: vascular carriers designed by mother nature |
| Q38972974 | Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond |
| Q73656652 | Frozen platelets and platelet substitutes in transfusion medicine |
| Q37278074 | Hemostatic Nanoparticles Improve Survival Following Blunt Trauma Even after 1 Week Incubation at 50 °C. |
| Q33348326 | Hemostatic effects of polymerized albumin particles bearing rGPIa/IIa in thrombocytopenic mice |
| Q38168784 | Hemostatic strategies for traumatic and surgical bleeding |
| Q33334113 | Infusible platelet membranes improve hemostasis in thrombocytopenic blood: experimental studies under flow conditions |
| Q41470605 | Intravenous hemostat: nanotechnology to halt bleeding. |
| Q41215308 | Intravenous hemostatic nanoparticles increase survival following blunt trauma injury |
| Q38148673 | Intravenous hemostats: challenges in translation to patients |
| Q30584438 | Intravenously administered nanoparticles increase survival following blast trauma |
| Q33373596 | New strategy of platelet substitutes for enhancing platelet aggregation at high shear rates: cooperative effects of a mixed system of fibrinogen gamma-chain dodecapeptide- or glycoprotein Ibalpha-conjugated latex beads under flow conditions |
| Q36703526 | Non-affinity factors modulating vascular targeting of nano- and microcarriers |
| Q74796234 | Novel platelet products and substitutes |
| Q33334939 | Platelet substitutes and novel platelet products |
| Q90422944 | Platelet transfusion: Current challenges |
| Q34579964 | Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries |
| Q40989773 | Platelet-like particle production from cultured human megakaryocytic cell line |
| Q47245873 | Preparation and characterization of 'heparinocytes': erythrocytes with covalently bound low molecular weight heparin |
| Q36870018 | Red Cell-Mediated Therapy: Opportunities and Challenges |
| Q33909935 | Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen |
| Q35858739 | Synthetic Strategies for Engineering Intravenous Hemostats |
| Q30514795 | Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis |
| Q33944023 | The erythrocyte viral trap: transgenic expression of viral receptor on erythrocytes attenuates coxsackievirus B infection |
| Q42579276 | Tuning ligand density on intravenous hemostatic nanoparticles dramatically increases survival following blunt trauma |
Search more.